May 11 (Reuters) – Hims & Hers Health raised its 2026 revenue forecast on Monday, betting on increased sales for its personalized healthcare offerings.
The company now expects annual revenue between $2.8 billion and $3 billion, compared with its previous forecast of $2.7 billion to $2.9 billion.
In March, Hims said it would partner with Novo Nordisk to offer its blockbuster weight-loss drug, Wegovy, on its platform, ending a legal dispute between the companies.
The dispute had followed Hims’ launch of a low-cost compounded alternative to Wegovy, which it has since discontinued.
Hims expects second-quarter revenue in the range of $680 million to $700 million, compared with analysts’ average estimate of $642.95 million, according to data compiled by LSEG.
Shares of the company were down 6% at $27.20 in after-market trading.
(Reporting by Siddhi Mahatole and Amina Niasse; Editing by Shinjini Ganguli)
Comments